ZOLTNERS ANDRIS A 4
4 · Adaptive Biotechnologies Corp · Filed Jul 3, 2019
Insider Transaction Report
Form 4
ZOLTNERS ANDRIS A
Director
Transactions
- Conversion
Series C Preferred Stock
2019-07-01−1,895,806→ 0 total→ Common Stock (1,895,806 underlying) - Conversion
Common Stock
2019-07-01+300,000→ 300,000 total - Conversion
Common Stock
2019-07-01+454,545→ 3,642,934 total - Conversion
Series B Preferred Stock
2019-07-01−992,583→ 0 total→ Common Stock (992,583 underlying) - Conversion
Series A Preferred Stock
2019-07-01−300,000→ 0 total→ Common Stock (300,000 underlying) - Conversion
Series F Preferred Stock
2019-07-01−223,082→ 0 total→ Common Stock (223,082 underlying) - Conversion
Common Stock
2019-07-01+992,583→ 1,292,583 total - Conversion
Common Stock
2019-07-01+1,895,806→ 3,188,389 total - Conversion
Common Stock
2019-07-01+223,082→ 3,866,016 total - Conversion
Series E-1 Preferred Stock
2019-07-01−454,545→ 0 total→ Common Stock (454,545 underlying)
Footnotes (5)
- [F1]Reflects automatic conversion of Series A Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock.
- [F2]Reflects automatic conversion of Series B Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock.
- [F3]Reflects automatic conversion of Series C Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock.
- [F4]Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock.
- [F5]Reflects automatic conversion of Series F Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock.